Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary s… Read more
Abbott Laboratories (ABT) - Net Assets
Latest net assets as of September 2025: $51.26 Billion USD
Based on the latest financial reports, Abbott Laboratories (ABT) has net assets worth $51.26 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($84.18 Billion) and total liabilities ($32.92 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $51.26 Billion |
| % of Total Assets | 60.9% |
| Annual Growth Rate | 8.67% |
| 5-Year Change | 45.14% |
| 10-Year Change | 98.92% |
| Growth Volatility | 10.38 |
Abbott Laboratories - Net Assets Trend (1985–2024)
This chart illustrates how Abbott Laboratories's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Abbott Laboratories (1985–2024)
The table below shows the annual net assets of Abbott Laboratories from 1985 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $47.90 Billion | +23.37% |
| 2023-12-31 | $38.83 Billion | +5.21% |
| 2022-12-31 | $36.91 Billion | +2.45% |
| 2021-12-31 | $36.02 Billion | +9.15% |
| 2020-12-31 | $33.00 Billion | +5.44% |
| 2019-12-31 | $31.30 Billion | +1.88% |
| 2018-12-31 | $30.72 Billion | -1.21% |
| 2017-12-31 | $31.10 Billion | +34.85% |
| 2016-12-31 | $23.06 Billion | -4.23% |
| 2015-12-31 | $24.08 Billion | -0.31% |
| 2014-12-31 | $24.16 Billion | -4.40% |
| 2013-12-31 | $25.27 Billion | -5.77% |
| 2012-12-31 | $26.81 Billion | +9.33% |
| 2011-12-31 | $24.53 Billion | +3.98% |
| 2010-12-31 | $23.59 Billion | +2.27% |
| 2009-12-31 | $23.06 Billion | +31.95% |
| 2008-12-31 | $17.48 Billion | -1.68% |
| 2007-12-31 | $17.78 Billion | +26.50% |
| 2006-12-31 | $14.05 Billion | -2.50% |
| 2005-12-31 | $14.42 Billion | +0.62% |
| 2004-12-31 | $14.33 Billion | +9.59% |
| 2003-12-31 | $13.07 Billion | +22.58% |
| 2002-12-31 | $10.66 Billion | +17.72% |
| 2001-12-31 | $9.06 Billion | +5.70% |
| 2000-12-31 | $8.57 Billion | +15.39% |
| 1999-12-31 | $7.43 Billion | +30.00% |
| 1998-12-31 | $5.71 Billion | +14.30% |
| 1997-12-31 | $5.00 Billion | +3.70% |
| 1996-12-31 | $4.82 Billion | +9.63% |
| 1995-12-31 | $4.40 Billion | +8.58% |
| 1994-12-31 | $4.05 Billion | +10.19% |
| 1993-12-31 | $3.67 Billion | +9.78% |
| 1992-12-31 | $3.35 Billion | +4.51% |
| 1991-12-31 | $3.20 Billion | +13.04% |
| 1990-12-31 | $2.83 Billion | +3.93% |
| 1989-12-31 | $2.73 Billion | +10.62% |
| 1988-12-31 | $2.46 Billion | +17.73% |
| 1987-12-31 | $2.09 Billion | +17.69% |
| 1986-12-31 | $1.78 Billion | -4.91% |
| 1985-12-31 | $1.87 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Abbott Laboratories's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2462.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $47.26 Billion | 99.15% |
| Common Stock | $25.15 Billion | 52.77% |
| Other Comprehensive Income | $-7.91 Billion | -16.59% |
| Total Equity | $47.66 Billion | 100.00% |
Abbott Laboratories Competitors by Market Cap
The table below lists competitors of Abbott Laboratories ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Citigroup Inc
NYSE:C
|
$192.16 Billion |
|
KLA-Tencor Corporation
NASDAQ:KLAC
|
$192.38 Billion |
|
Nextera Energy Inc
NYSE:NEE
|
$192.91 Billion |
|
Amgen Inc
NASDAQ:AMGN
|
$194.15 Billion |
|
KLA Corp.
LSE:0JPO
|
$190.97 Billion |
|
Novartis AG
PINK:NVSEF
|
$190.10 Billion |
|
Australia and New Zealand Banking Group Ltd
AU:AN3PK
|
$189.74 Billion |
|
Morgan Stanley
NYSE:MS
|
$189.65 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Abbott Laboratories's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 38,603,000,000 to 47,664,000,000, a change of 9,061,000,000 (23.5%).
- Net income of 13,402,000,000 contributed positively to equity growth.
- Dividend payments of 3,836,000,000 reduced retained earnings.
- Share repurchases of 1,295,000,000 reduced equity.
- Other comprehensive income decreased equity by 67,000,000.
- Other factors increased equity by 857,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $13.40 Billion | +28.12% |
| Dividends Paid | $3.84 Billion | -8.05% |
| Share Repurchases | $1.29 Billion | -2.72% |
| Other Comprehensive Income | $-67.00 Million | -0.14% |
| Other Changes | $857.00 Million | +1.8% |
| Total Change | $- | 23.47% |
Book Value vs Market Value Analysis
This analysis compares Abbott Laboratories's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.06x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 110.15x to 4.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $1.01 | $110.71 | x |
| 1986-12-31 | $0.95 | $110.71 | x |
| 1987-12-31 | $1.16 | $110.71 | x |
| 1988-12-31 | $1.38 | $110.71 | x |
| 1989-12-31 | $1.55 | $110.71 | x |
| 1990-12-31 | $1.64 | $110.71 | x |
| 1991-12-31 | $1.88 | $110.71 | x |
| 1992-12-31 | $2.00 | $110.71 | x |
| 1993-12-31 | $2.22 | $110.71 | x |
| 1994-12-31 | $2.49 | $110.71 | x |
| 1995-12-31 | $2.76 | $110.71 | x |
| 1996-12-31 | $3.05 | $110.71 | x |
| 1997-12-31 | $3.17 | $110.71 | x |
| 1998-12-31 | $3.66 | $110.71 | x |
| 1999-12-31 | $4.77 | $110.71 | x |
| 2000-12-31 | $5.47 | $110.71 | x |
| 2001-12-31 | $5.78 | $110.71 | x |
| 2002-12-31 | $6.78 | $110.71 | x |
| 2003-12-31 | $8.32 | $110.71 | x |
| 2004-12-31 | $9.12 | $110.71 | x |
| 2005-12-31 | $9.22 | $110.71 | x |
| 2006-12-31 | $9.15 | $110.71 | x |
| 2007-12-31 | $11.40 | $110.71 | x |
| 2008-12-31 | $11.20 | $110.71 | x |
| 2009-12-31 | $14.88 | $110.71 | x |
| 2010-12-31 | $14.57 | $110.71 | x |
| 2011-12-31 | $15.56 | $110.71 | x |
| 2012-12-31 | $16.78 | $110.71 | x |
| 2013-12-31 | $15.99 | $110.71 | x |
| 2014-12-31 | $14.10 | $110.71 | x |
| 2015-12-31 | $14.08 | $110.71 | x |
| 2016-12-31 | $13.85 | $110.71 | x |
| 2017-12-31 | $17.67 | $110.71 | x |
| 2018-12-31 | $17.25 | $110.71 | x |
| 2019-12-31 | $17.46 | $110.71 | x |
| 2020-12-31 | $18.36 | $110.71 | x |
| 2021-12-31 | $20.01 | $110.71 | x |
| 2022-12-31 | $20.80 | $110.71 | x |
| 2023-12-31 | $22.07 | $110.71 | x |
| 2024-12-31 | $27.27 | $110.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Abbott Laboratories utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 28.12%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 31.95%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.71x
- Recent ROE (28.12%) is above the historical average (24.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 24.87% | 13.85% | 0.97x | 1.85x | $278.23 Million |
| 1986 | 30.38% | 14.20% | 0.98x | 2.17x | $362.61 Million |
| 1987 | 30.22% | 14.42% | 1.00x | 2.09x | $423.25 Million |
| 1988 | 30.51% | 15.23% | 1.02x | 1.96x | $505.54 Million |
| 1989 | 31.54% | 15.98% | 1.11x | 1.78x | $587.16 Million |
| 1990 | 34.08% | 15.68% | 1.11x | 1.96x | $682.44 Million |
| 1991 | 33.99% | 15.83% | 1.10x | 1.95x | $768.50 Million |
| 1992 | 37.01% | 15.78% | 1.13x | 2.07x | $904.34 Million |
| 1993 | 38.07% | 16.64% | 1.09x | 2.09x | $1.03 Billion |
| 1994 | 37.45% | 16.56% | 1.07x | 2.10x | $1.11 Billion |
| 1995 | 38.41% | 16.87% | 1.06x | 2.14x | $1.25 Billion |
| 1996 | 39.04% | 17.09% | 0.99x | 2.31x | $1.40 Billion |
| 1997 | 41.59% | 17.50% | 0.99x | 2.41x | $1.58 Billion |
| 1998 | 40.86% | 18.71% | 0.94x | 2.31x | $1.76 Billion |
| 1999 | 32.93% | 18.56% | 0.91x | 1.95x | $1.70 Billion |
| 2000 | 32.51% | 20.27% | 0.90x | 1.78x | $1.93 Billion |
| 2001 | 17.11% | 9.52% | 0.70x | 2.57x | $644.45 Million |
| 2002 | 26.20% | 15.80% | 0.73x | 2.27x | $1.73 Billion |
| 2003 | 21.06% | 13.99% | 0.74x | 2.04x | $1.45 Billion |
| 2004 | 22.59% | 16.44% | 0.68x | 2.01x | $1.80 Billion |
| 2005 | 23.39% | 15.10% | 0.77x | 2.02x | $1.93 Billion |
| 2006 | 12.22% | 7.64% | 0.62x | 2.57x | $311.34 Million |
| 2007 | 20.28% | 13.92% | 0.65x | 2.23x | $1.83 Billion |
| 2008 | 27.92% | 16.53% | 0.70x | 2.43x | $3.13 Billion |
| 2009 | 24.83% | 18.68% | 0.59x | 2.27x | $3.43 Billion |
| 2010 | 20.40% | 13.15% | 0.58x | 2.67x | $2.36 Billion |
| 2011 | 19.35% | 12.17% | 0.64x | 2.47x | $2.28 Billion |
| 2012 | 22.32% | 14.95% | 0.59x | 2.52x | $3.29 Billion |
| 2013 | 10.23% | 11.79% | 0.51x | 1.71x | $58.90 Million |
| 2014 | 10.61% | 11.28% | 0.46x | 2.03x | $131.40 Million |
| 2015 | 20.85% | 21.68% | 0.46x | 2.07x | $2.30 Billion |
| 2016 | 6.82% | 6.71% | 0.38x | 2.68x | $-653.80 Million |
| 2017 | 1.54% | 1.74% | 0.36x | 2.47x | $-2.61 Billion |
| 2018 | 7.76% | 7.74% | 0.46x | 2.20x | $-684.40 Million |
| 2019 | 11.86% | 11.56% | 0.47x | 2.18x | $578.20 Million |
| 2020 | 13.71% | 12.99% | 0.48x | 2.21x | $1.22 Billion |
| 2021 | 19.75% | 16.42% | 0.57x | 2.10x | $3.49 Billion |
| 2022 | 18.90% | 15.88% | 0.59x | 2.03x | $3.26 Billion |
| 2023 | 14.83% | 14.27% | 0.55x | 1.90x | $1.86 Billion |
| 2024 | 28.12% | 31.95% | 0.52x | 1.71x | $8.64 Billion |
Industry Comparison
This section compares Abbott Laboratories's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $236,368,173
- Average return on equity (ROE) among peers: -32.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Abbott Laboratories (ABT) | $51.26 Billion | 24.87% | 0.64x | $191.37 Billion |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |